AURX Revenue Soars 128% Amidst Mounting Losses, Going Concern Doubt

TL;DR

**AURX's revenue jump is a mirage; the 'going concern' warning means this stock is a speculative gamble, not an investment.**

AI Summary

Nuo Therapeutics, Inc. (AURX) reported a significant increase in total revenue for the nine months ended September 30, 2025, reaching $2,216,679, up from $970,301 in the same period of 2024, representing a 128.4% increase. Product sales surged to $2,066,679 from $970,301, and distribution fee revenue, primarily from a $1.5 million upfront payment from Smith+Nephew, contributed $150,000. Despite this revenue growth, the company's net loss widened slightly to $1,933,736 for the nine months ended September 30, 2025, compared to a net loss of $1,827,039 in the prior year. Operating expenses, specifically selling, general, and administrative costs, increased to $3,466,898 from $2,582,472. The company's accumulated deficit grew to approximately $34.2 million as of September 30, 2025, and its cash balance was approximately $0.5 million. AURX explicitly stated substantial doubt about its ability to continue as a going concern for the next 12 months due to insufficient current resources and projected revenue to support operations.

Why It Matters

Nuo Therapeutics' substantial revenue growth, driven by product sales and a significant distribution fee from Smith+Nephew, signals potential market traction for its Aurix System. However, the widening net loss and explicit 'going concern' warning raise serious red flags for investors, indicating that increased sales are not yet translating into profitability or financial stability. This precarious financial position could impact employee morale and job security, while customers might face uncertainty regarding long-term product support. In a competitive medical device market, AURX's struggle to achieve sustainable operations despite a favorable CMS National Coverage Determination for Aurix highlights the immense capital requirements and operational challenges in the biotech sector.

Risk Assessment

Risk Level: high — Nuo Therapeutics explicitly states "substantial doubt about our ability to continue as a going concern" for the next 12 months, citing insufficient current resources and projected revenue. The company's accumulated deficit reached approximately $34.2 million as of September 30, 2025, with only $0.5 million in cash, indicating a severe liquidity crunch despite increased revenue.

Analyst Insight

Investors should avoid Nuo Therapeutics (AURX) given the explicit 'going concern' warning and persistent net losses despite revenue growth. The company's need for significant additional capital, with potential for substantial dilution, makes it a high-risk speculative play rather than a viable long-term investment.

Financial Highlights

debt To Equity

N/A

revenue

$2,216,679

operating Margin

N/A

total Assets

$1,927,637

total Debt

$2,347,243

net Income

$ -1,933,736

eps

$ -0.01

gross Margin

28.3%

cash Position

$514,797

revenue Growth

+128.4%

Revenue Breakdown

Key Numbers

• $2.22M — Total Revenue (Increased 128.4% for the nine months ended September 30, 2025, from $970,301 in 2024.)
• $1.93M — Net Loss (Widened for the nine months ended September 30, 2025, from $1.83M in 2024.)
• $34.2M — Accumulated Deficit (Increased as of September 30, 2025, highlighting persistent unprofitability.)
• $514,797 — Cash (Low cash balance as of September 30, 2025, contributing to going concern doubt.)
• 128.4% — Revenue Growth (Percentage increase in total revenue for the nine months ended September 30, 2025, compared to 2024.)
• $1.5M — Distribution Fee Revenue (Upfront payment from Smith+Nephew, a key driver of revenue growth.)
• $3.47M — Selling, General and Administrative Expenses (Increased for the nine months ended September 30, 2025, contributing to net loss.)

Key Players & Entities

• Nuo Therapeutics, Inc. (company) — Registrant
• Smith+Nephew (company) — Partner in private label distribution agreement
• U. S. Food and Drug Administration (regulator) — Granted 510(k) clearance for AutoloGel System
• Centers for Medicare & Medicaid Services (regulator) — Issued favorable National Coverage Determination for Aurix
• Pfizer (company) — Exclusive supplier of bovine thrombin reagent
• $2,216,679 (dollar_amount) — Total revenue for nine months ended September 30, 2025
• $1,933,736 (dollar_amount) — Net loss for nine months ended September 30, 2025
• $34.2 million (dollar_amount) — Accumulated deficit as of September 30, 2025
• $0.5 million (dollar_amount) — Cash balance as of September 30, 2025
• Aldagen, Inc. (company) — Non-operational, wholly owned subsidiary

FAQ

Risk Factors

• Going Concern Doubt [high — financial]: The company has a substantial doubt about its ability to continue as a going concern for the next 12 months due to insufficient current resources and projected revenue to support operations. As of September 30, 2025, cash was $514,797 and the accumulated deficit was $34,193,682.
• Negative Stockholders' Equity [high — financial]: Total stockholders' deficit was $419,606 as of September 30, 2025, indicating liabilities exceed assets. This is a deterioration from positive equity of $513,712 at December 31, 2024.
• Dependence on Key Partnerships [medium — operational]: The company's revenue generation, particularly the recent distribution fee revenue from Smith+Nephew, highlights a reliance on strategic partnerships. The success and continuation of these agreements are critical for future revenue.
• Increasing Operating Expenses [medium — financial]: Selling, general, and administrative expenses increased to $3,466,898 for the nine months ended September 30, 2025, from $2,582,472 in the prior year, contributing to the widening net loss.
• FDA and CMS Relevancy [medium — regulatory]: The company's history includes reliance on FDA clearance (Aurix System) and CMS National Coverage Determination for reimbursement. Changes in regulatory landscape or coverage decisions could significantly impact operations.

Industry Context

Nuo Therapeutics operates in the regenerative medicine and wound care sector, which is characterized by innovation in therapies like platelet-rich plasma (PRP) and cell-based treatments. The industry is competitive, with established players and emerging biotech firms vying for market share. Regulatory approvals and reimbursement policies, particularly from entities like CMS, are critical determinants of commercial success for such specialized medical products.

Regulatory Implications

The company's reliance on FDA clearance for its Aurix System and CMS coverage decisions for reimbursement presents ongoing regulatory risks. Any changes in these regulatory frameworks or adverse coverage decisions could significantly impact Nuo's ability to generate revenue and sustain operations.

What Investors Should Do

1. Monitor cash burn and future financing activities.
2. Assess the sustainability of revenue growth.
3. Evaluate the path to profitability.
4. Understand the implications of the going concern warning.

Key Dates

• 2025-09-30: Nine months ended reporting period — Shows significant revenue growth but also a widening net loss and a critical cash position, leading to going concern doubt.
• 2025-07-30: Security Purchase Agreement closed — Raised $113,541 in proceeds from sale of common stock, a small but necessary capital infusion.
• 2025-01-01: Start of nine months ended September 30, 2025 period — Marks the beginning of the period with substantial revenue growth driven by product sales and distribution fees.
• 2024-12-31: Year-end reporting period — Previous period's financial standing, showing positive stockholders' equity ($513,712) and lower total liabilities ($675,796).
• 2024-09-30: Nine months ended reporting period (prior year) — Baseline for comparison, showing significantly lower revenue ($970,301) and a smaller net loss ($1,827,039).

Glossary

Accumulated deficit

The total net losses of a company since its inception that have not been offset by net income. (Indicates the company's historical unprofitability, which has grown to $34,193,682 as of September 30, 2025.)

Going concern

An assumption that a company will continue to operate for the foreseeable future, typically at least the next 12 months. (Nuo Therapeutics has explicitly stated substantial doubt about its ability to continue as a going concern, a critical warning for investors.)

Product sales

Revenue generated from the sale of the company's manufactured goods or services. (This is a primary revenue stream for Nuo Therapeutics, showing significant growth to $2,066,679 for the nine months ended September 30, 2025.)

Distribution fee revenue

Revenue earned for facilitating the distribution of products, often through partnerships or agreements. (A new and significant contributor for Nuo, including a $1.5 million upfront payment from Smith+Nephew, boosting total revenue.)

Stockholders' equity/(deficit)

The residual interest in the assets of an entity after deducting all its liabilities. A deficit means liabilities exceed assets. (Nuo Therapeutics has a stockholders' deficit of $419,606 as of September 30, 2025, a key indicator of financial distress.)

National Coverage Determination (NCD)

A decision by the Centers for Medicare & Medicaid Services (CMS) that determines whether a particular item or service is considered reasonable and necessary for Medicare beneficiaries. (A favorable NCD for the Aurix System was crucial for Nuo to restart business activities and impacts its revenue potential.)

Year-Over-Year Comparison

Compared to the prior year's nine-month period, Nuo Therapeutics has demonstrated impressive revenue growth of 128.4%, largely driven by product sales and a significant distribution fee from Smith+Nephew. However, this top-line improvement has not translated into profitability, as the net loss has slightly widened from $1,827,039 to $1,933,736. Operating expenses, particularly SG&A, have increased substantially. The company's financial position has also deteriorated, moving from positive stockholders' equity to a deficit, and its cash position remains critically low, leading to a severe going concern warning not present in the prior filing.

Key Financial Figures

• $0.0001 — nding of the registrant's common stock, $0.0001 par value, was 48,077,745 . Table of C

Filing Documents

• aurx20250930_10q.htm (10-Q) — 771KB
• ex_871658.htm (EX-31) — 12KB
• ex_871659.htm (EX-32) — 5KB
• logo.jpg (GRAPHIC) — 5KB
• 0001437749-25-032437.txt ( ) — 4433KB
• aurx-20250930.xsd (EX-101.SCH) — 43KB
• aurx-20250930_cal.xml (EX-101.CAL) — 31KB
• aurx-20250930_def.xml (EX-101.DEF) — 296KB
• aurx-20250930_lab.xml (EX-101.LAB) — 265KB
• aurx-20250930_pre.xml (EX-101.PRE) — 321KB
• aurx20250930_10q_htm.xml (XML) — 600KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Unaudited Consolidated Financial Statements

Item 1. Unaudited Consolidated Financial Statements 1

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 15

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 22

Controls and Procedures

Item 4. Controls and Procedures 22

OTHER INFORMATION

PART II. OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 23

Risk Factors

Item 1A. Risk Factors 23

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 23

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 23

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 23

Other Information

Item 5. Other Information 23

Exhibits

Item 6. Exhibits 24

Signatures

Signatures 25 Table of Contents PART I FINANCIAL INFORMATION

Consolidated Financial Statements

Item 1. Consolidated Financial Statements NUO THERAPEUTICS, INC. CONSOLIDATED BALANCE SHEETS (Unaudited) September 30, 2025 December 31, 2024 ASSETS Current assets Cash $ 514,797 $ 283,714 Accounts receivable, net 652,252 248,205 Inventory, net 201,627 150,442 Prepaid expenses and other current assets 93,977 159,185 Total current assets 1,462,653 841,546 Property and equipment, net 347,022 177,022 Operating lease right of use assets 117,962 170,940 Total assets $ 1,927,637 $ 1,189,508 LIABILITIES AND STOCKHOLDERS' EQUITY/(DEFICIT) Current liabilities Accounts payable $ 491,659 $ 219,190 Accrued expenses 390,892 292,400 Deferred revenue 300,000 - Current portion of operating lease liabilities 73,935 66,861 Total current liabilities 1,256,486 578,451 Deferred revenue – long term 1,050,000 - Non-current portion of operating lease liabilities 40,757 97,345 Total liabilities 2,347,243 675,796 Commitments and contingencies (Note 8) Stockholders' equity/(deficit) Common stock; $ 0.0001 par value, 100,000,000 shares authorized, 47,881,121 and 46,816,114 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively 4,788 4,682 Additional paid-in capital 33,769,288 32,768,976 Accumulated deficit ( 34,193,682 ) ( 32,259,946 ) Total stockholders' equity/(deficit) ( 419,606 ) 513,712 Total liabilities and stockholders' equity/(deficit) $ 1,927,637 $ 1,189,508 See accompanying notes to unaudited consolidated financial statements. 1 Table of Contents NUO THERAPEUTICS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Three Months ended September 30, 2025 Three Months ended September 30, 2024 Revenue Product sales $ 957,096 $ 370,951 Distribution fee revenue 75,000 - Total revenue 1,032,096 370,951 Costs of sales 406,721 100,504 Gross profit 625,375

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) Note 1 – Description of Business Description of Business Nuo Therapeutics, Inc. is a Delaware corporation organized in 1998 under the name Informatix Holdings, Inc. In 1999, Autologous Wound Therapy, Inc., an Arkansas Corporation, merged with and into Informatix Holdings, Inc. and the name of the surviving corporation was changed to Autologous Wound Therapy, Inc. In 2000, Autologous Wound Therapy, Inc. changed its name to Cytomedix, Inc. ("Cytomedix"). In 2001, Cytomedix, filed for bankruptcy, from which it emerged in 2002 under a Plan of Reorganization. In September 2007, Cytomedix received Section 510(k) clearance from the U. S. Food and Drug Administration ("FDA") for the AutoloGel System, now known as the Aurix System ("Aurix"), for processing peripheral blood into an autologous platelet rich plasma ("PRP") for wound management. In 2012, Cytomedix, acquired Aldagen, Inc. ("Aldagen"), a privately held developmental cell-therapy company. Aldagen remains a non-operational, wholly owned subsidiary of the Company. In 2014, Cytomedix changed its name to Nuo Therapeutics, Inc. In 2016, Nuo filed for and emerged from bankruptcy under a Chapter 11 Plan of Reorganization. Effective May 1, 2019, Nuo furloughed its remaining employees and ceased standard operational activities as it awaited developments concerning its reconsideration request with the Centers for Medicare & Medicaid Services ("CMS") regarding Medicare coverage for Aurix. In April 2021, CMS issued a favorable National Coverage Determination ("NCD") for autologous PRP products and Nuo restarted business activities in October 2021. Nuo's principal offices are located in Houston, Texas. Note 2 – Liquidity and Summary of Significant Accounting Principles Liquidity Since our inception, we have financed our operations by raising debt, issuing equity and equity-linked instruments, and executing licensing arrangements, and to a lesser extent by gen

View Full Filing

View this 10-Q filing on SEC EDGAR